Key result
Upper body non-visceral fat, not visceral fat, drives most systemic free fatty acid release.
OBJECTIVE: To review the evidence for and against the role of visceral adipose tissue as a major contributor to the metabolic complications of obesity through abnormal regulation of lipolysis. RESEARCH METHODS AND PROCEDURES: Data from investigators in the field who have studied visceral adiposity and metabolic health and/or regional and systemic free fatty acid (FFA) release were considered. RESULTS: Although visceral fat mass was positively correlated with adverse health consequences and excess FFA availability, visceral fat was not the source of excess systemic FFA availability. Upper body non-visceral fat contributes the majority of FFAs in lean, obese, diabetic, and non-diabetic humans. Increasing amounts of visceral fat probably result in greater hepatic FFA delivery. DISCUSSION: Systemic, as opposed to hepatic, insulin resistance is unlikely to be caused by high rates of visceral adipose tissue lipolysis.
No takes yet. Share an insight, caveat, or question.
Michael D. Jensen (2006) conducted a review in Metabolic syndrome. Visceral adipose tissue was evaluated on Systemic free fatty acid (FFA) release and insulin resistance. Although visceral fat correlates with adverse health outcomes, upper body non-visceral fat contributes the majority of systemic free fatty acids, making visceral lipolysis an unlikely cause of systemic insulin resistance.
Synapse has enriched 5 related papers. Consider them for comparative context: